Through the 90-day period concluding February 19, 2026, Coeptis Therapeutics Holdings's top three insider stakeholders include Director Chris Calise (368.74K shares), Ceo And President David Mehalick (330.19K shares), Vp Operations Daniel Alexander Yerace (70.53K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Capital, Llc Glazer | 48,221 | 26 May, 2021 | |
| Circle Investments, Llc Harraden | 21,457 | 06 May, 2022 | |
| Chris Calise | 368,741 | 13 Feb, 2026 | |
| David Mehalick | Ceo And President | 330,192 | 13 Feb, 2026 |
| Daniel Alexander Yerace | Vp Operations | 70,531 | 13 Feb, 2026 |
| Christine Elise Sheehy | Vp Compliance And Secy | 64,031 | 13 Feb, 2026 |
| Gene Salkind | 14,593 | 13 Feb, 2026 | |
| Brian Cogley | Chief Financial Officer | 22,500 | 13 Feb, 2026 |
| Philippe Deschamps | 8,950 | 13 Feb, 2026 | |
| Christopher P. Cochran | 8,950 | 13 Feb, 2026 | |
| Tara Desilva | 8,950 | 13 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 11 Feb, 2026 | Gene Salkind | Common Stock | A | 3,250 | $0.00 | 13,161 | D | A |
| 11 Feb, 2026 | Gene Salkind | Common stock | A | 5,700 | $10.56 | 13,161 | D | M |
| 11 Feb, 2026 | Philippe Deschamps | Common stock | A | 5,700 | $10.56 | 8,950 | D | M |
| 11 Feb, 2026 | Philippe Deschamps | Common Stock | A | 3,250 | $0.00 | 8,950 | D | A |
| 11 Feb, 2026 | Chris Calise | Common stock | A | 3,250 | $0.00 | 368,741 | D | A |
| 11 Feb, 2026 | Chris Calise | Common stock | A | 5,700 | $10.56 | 368,741 | D | M |
| 11 Feb, 2026 | David Mehalick | Common stock | A | 148,875 | $7.05 | 330,192 | D | M |
| 11 Feb, 2026 | David Mehalick | Common Stock | A | 51,250 | $0.00 | 330,192 | D | A |
| 11 Feb, 2026 | Daniel Alexander Yerace | Common Stock | A | 20,000 | $0.00 | 70,531 | D | A |
| 11 Feb, 2026 | Daniel Alexander Yerace | Common stock | A | 10,000 | $10.41 | 70,531 | D | M |
| 11 Feb, 2026 | Christine Elise Sheehy | Common stock | A | 1,000 | $10.56 | 64,031 | D | M |
| 11 Feb, 2026 | Christine Elise Sheehy | Common Stock | A | 12,500 | $0.00 | 64,031 | D | A |
| 11 Feb, 2026 | Christopher P. Cochran | Common stock | A | 5,700 | $10.56 | 8,950 | D | M |
| 11 Feb, 2026 | Christopher P. Cochran | Common Stock | A | 3,250 | $0.00 | 8,950 | D | A |
| 11 Feb, 2026 | Tara Desilva | Common stock | A | 5,700 | $10.56 | 8,950 | D | M |
| 11 Feb, 2026 | Tara Desilva | Common Stock | A | 3,250 | $0.00 | 8,950 | D | A |
| 11 Feb, 2026 | Brian Cogley | Common stock | A | 10,000 | $10.56 | 22,500 | D | M |
| 11 Feb, 2026 | Brian Cogley | Common Stock | A | 12,500 | $0.00 | 22,500 | D | A |
| 12 Jan, 2024 | Tara Desilva | Common Stock | A | 1,800 | $0.58 | 1,613 | D | P |
| 12 Jan, 2024 | Tara Desilva | Common Stock | A | 466 | $0.56 | 1,523 | D | P |